BEST of ASCO Portugal 2024 - IF
Abstract
At the ASCO 2024 annual meeting, which took place in Chicago, from January 31 to February 4, 2024, very relevant works were presented in the most diverse areas of Oncology.
With regard to the work carried out on esophagogastric and hepatobilipancreatic tumors, 3 clinical trials were selected, due to their possible impact on daily clinical practice, to be presented and discussed, in Coimbra, on July 5th, at BEST OF ASCO PORTUGAL 2024, organized by the Brazilian Society of Oncology.
Downloads
References
Al-Batran S-E, Homann N, Pauligk C et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
Shapiro J, van Lanschot J , Hulshof M et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.
Kelly R, Ajani J, Kuzdzal J et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 2021; 384:1191-1203. DOI: 10.1056/NEJMoa2032125.
Janjigian Y, Van Cutsem E, Muro K et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093.
Shitara K, Rha S, Wyrwicz L et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7.
Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 2011;364: 1817-1825.DOI: 10.1056/NEJMoa1011923.
Wainberg Z, Melisi D, Macarulla T et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1.
Goldstein D, El-Maraghi R, Hammel P et al. Nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015 Jan 31;107(2): dju413. doi: 10.1093/jnci/dju413.
Finn R, Qin S, Ikeda M et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382:1894-1905. DOI: 10.1056/NEJMoa1915745.
Abou-Alfa G, Lau G, Kudo M et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022 Aug;1(8): EVIDoa2100070. doi: 10.1056/EVIDoa2100070.
Qin S , Chan S , Gu S et al . Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3.
